Alexa Meara on Muck Rack

Alexa Meara

Columbus
As seen in: Everyday Health, Wiley Online Library, The BMJ, Healio, Healio Rheumatology, NewsBreak, American Journal of Managed Care, The Journal of Rheumatology, Targeted Oncology, Respiratory Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alexa

Contact Alexa, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Novel Use of Anifrolumab for a Novel Disease

|
By Zachary Holtz, Adam Schulz, Alexa Meara
| Wiley Online Library Verified
INTRODUCTION Saphnelo (anifrolumab-fnia) was approved by the Food and Drug Administration (FDA) in 2021 for the treatment of moderate-to-severe systemic lupus erythematosus (SLE).
Open in Who Shared Issue with article?

A Case of Steroid‐Dependent Immune Checkpoint Inhibitor Pneumonitis Treated With Subcutaneous Tocilizumab

|
By Nicole Chang, Alexa Meara, Kevin Ho
| Wiley Online Library Verified
1 Introduction Immune checkpoint proteins regulate the immune system response and prevent autoimmune-mediated tissue damage [1]. Tumour cells can evade detection by activating these proteins, leading to unregulated tumour cell growth and proliferation. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block tumour cells from activating immune checkpoint proteins, restoring the immune system's ability to detect and destroy cancer cells.
Open in Who Shared Issue with article?

Acknowledging and addressing real-world challenges to treating immune-related adverse events

|
By David E. Gerber, Bonnie Bermas, Alexa Meara
| The BMJ Verified
Immune related adverse event - irAE Immune Checkpoint Inhibitor Survivorship More than a decade into the remarkable era of cancer immunotherapy, we are facing major challenges with the toxicities of the revolutionary immune checkpoint inhibitor (ICI) therapies. While ICIs have substantially improved survival rates for melanoma and lung cancer among other malignancies, we are in the nascent stage of understanding and management of their adverse events.
Open in Who Shared Issue with article?
See all 13 licensed articles (158 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified